(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Get a good deal on Your Rooftop Substitution Venture - 221 Incredibly Entertaining Contemplations To Observe Consistently
- 3She was moments away from giving birth. The hospital discharged her
- 4Nature's Treats: 10 Organic products That Lift Prosperity
- 5Which Kind of Pet Makes the Incomparable Buddy?
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- 7 Moves toward a Sound and Dynamic Way of life
- Find Serenity: 10 Stunning Setting up camp Areas
- Beating Wellbeing Difficulties: Individual Victories in Health
- Thousands of ultra-orthodox protest in Jerusalem against conscription
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- Satellites capture aftermath of Ethiopian volcano's 1st eruption in recorded history (images)
- A definitive Manual for Well known Fragrances
- All the eclipses, supermoons, meteor showers and planets to spot in 2026
